QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

NCT06404736 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Early Breast Cancer
Neoadjuvant Therapy
TNBC, Triple Negative Breast Cancer

Interventions

DRUG: Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
DRUG: Albumin-bound paclitaxel
DRUG: Carboplatin

Sponsor

Fudan University